SCHEMBL22983284

SCHEMBL22983284

O=C(Nc1ccc(-c2cnco2)cc1)c1cccnc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 9/20 0.78
▸ RAB9A P51151 8/20 0.78
▸ ALDH1A1 P00352 4/20 0.78
▸ KDM4E B2RXH2 3/20 0.78
▸ LMNA P02545 3/20 0.78
▸ PKM P14618 2/20 0.78
▸ ROCK2 O75116 1/20 0.61
▸ ROCK1 Q13464 1/20 0.61
▸ HIF1A Q16665 1/20 0.58
▸ SMN1; SMN2 Q16637 5/20 0.56
▸ KMT2A Q03164 4/20 0.56
▸ MEN1 O00255 3/20 0.56
▸ TP53 P04637 2/20 0.56
▸ CYP3A4 P08684 2/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ MAPK1 P28482 1/20 0.55
▸ TDP1 Q9NUW8 1/20 0.55
▸ HTT P42858 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17491404 0.81 MEN1 (0.61) NPC1RAB9AALDH1A1KDM4ELMNA
SCHEMBL15652156 0.79 NPC1 (0.70) NPC1RAB9AALDH1A1KDM4ELMNA
SCHEMBL14083900 0.79 NPC1 (0.69) NPC1RAB9AALDH1A1KDM4ELMNA
SCHEMBL17109838 0.78 NPC1 (0.68) NPC1RAB9AALDH1A1KDM4ELMNA
SCHEMBL14027518 0.78 NPC1 (1.00) NPC1RAB9AALDH1A1KDM4ELMNA
SCHEMBL22983004 0.78 RAB9A (0.61) NPC1RAB9AALDH1A1KDM4ELMNA
SCHEMBL5384036 0.77 ROCK2 (0.76) NPC1RAB9AALDH1A1KDM4ELMNA
SCHEMBL27754792 0.77 ROCK2 (0.66) NPC1RAB9AALDH1A1LMNAROCK2
SCHEMBL14082980 0.77 NPC1 (0.70) NPC1RAB9AALDH1A1KDM4ELMNA
Nicotinanilide SCHEMBL352439 0.77 LMNA (0.83) NPC1RAB9AALDH1A1LMNAROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324899-A1 COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE METRO INTERNATIONAL BIOTECH, LLC 2022-10-13 — — US disclosed
EP-4013766-A1 COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE Metro International Biotech, LLC (US) 2022-06-22 — — EP disclosed
CN-114555619-A Compounds and compositions for differential modulation of nicotinamide adenine dinucleotide 麦德龙国际生物科技有限责任公司 2022-05-27 — — CN disclosed
WO-2021030551-A1 COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE METRO INTERNATIONAL BIOTECH, LLC (US) 2021-02-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324899-A1 COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE NQO1, NAMPT, NADK NPC1 309/4885RAB9A 1443/4885ALDH1A1 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback